Healthcare costs for allergic rhinitis patients on allergy immunotherapy: a retrospective observational study

2017 ◽  
Vol 33 (11) ◽  
pp. 2039-2047 ◽  
Author(s):  
Felicia Allen-Ramey ◽  
Jianbin Mao ◽  
Cori Blauer-Peterson ◽  
Marvin Rock ◽  
Robert Nathan ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Observational Study ◽  
Healthcare Costs ◽  
Retrospective Observational Study ◽  
Allergy Immunotherapy

Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study

2007 ◽  
Vol 23 (4) ◽  
pp. 721-730 ◽  
Author(s):  
Luis Borderias ◽  
Grzegorz Mincewicz ◽  
Pier Luigi Paggiaro ◽  
Magda Guilera ◽  
Vasilisa Sazonov Kocevar ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Observational Study ◽  
Asthma Control ◽  
Retrospective Observational Study

scholarly journals Healthcare costs associated with allergic rhinitis, asthma allergy immunotherapy

2019 ◽  
Author(s):  
F. Tesch ◽  
A. Domdey ◽  
T. Sydendal Grand ◽  
E. Wuestenberg ◽  
L. Elliott ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Healthcare Costs ◽  
Allergy Immunotherapy

Hemmkörperentwicklung bei Hämophilie-Patienten nach Präparate wechsel

2012 ◽  
Vol 32 (S 01) ◽  
pp. S39-S42 ◽  
Author(s):  
S. Kocher ◽  
G. Asmelash ◽  
V. Makki ◽  
S. Müller ◽  
S. Krekeler ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Observational Study ◽  
Retrospective Observational Study ◽  
Frequent Change ◽  
Patient Age ◽  
Treatment Regimens ◽  
Patient Âgé ◽  
The Relationship ◽  
Observation Period

SummaryThe retrospective observational study surveys the relationship between development of inhibitors in the treatment of haemophilia patients and risk factors such as changing FVIII products. A total of 119 patients were included in this study, 198 changes of FVIII products were evaluated. Results: During the observation period of 12 months none of the patients developed an inhibitor, which was temporally associated with a change of FVIII products. A frequent change of FVIII products didn’t lead to an increase in inhibitor risk. The change between plasmatic and recombinant preparations could not be confirmed as a risk factor. Furthermore, no correlation between treatment regimens, severity, patient age and comorbidities of the patients could be found.

Sign in / Sign up

Export Citation Format

Share Document